GDMT first is not a placeholder — secondary MR may improve
In secondary MR, optimizing heart failure therapy is not a delay tactic — it is often the first effective treatment for the mechanism causing the regurgitation. GDMT can reduce MR severity, and in selected patients, MR may improve enough to change the management trajectory.
When a patient with severe secondary MR is told to 'optimize GDMT first,' it can sound as if the valve problem is being postponed. That is not the right framing. In secondary MR, GDMT is the first-line treatment for the underlying disease process. This changes the perioperative conversation: is this a patient who needs valve-intervention evaluation now, or a patient whose HF therapy has not yet been optimized?
Key takeaway
Secondary MR is a consequence of LV or atrial remodeling — and remodeling can improve with treatment. Disease-modifying HF therapies — ACEi/ARB/ARNI, beta-blockers, MRA, and SGLT2 inhibitors — can improve outcomes and promote reverse remodeling. Diuretics reduce congestion and filling pressures. As LV volume, wall stress, filling pressure, and synchrony improve, the geometric basis for MR may improve. Skipping GDMT and moving directly to valve intervention may bypass a treatment that can reduce MR in many patients.
Key points
- Secondary MR reflects the hemodynamic state of a remodeled LV or dilated LA — and that state can change with therapy.
- Disease-modifying HF therapies — ACEi/ARB/ARNI, beta-blockers, MRA, and SGLT2 inhibitors — can improve HF outcomes and promote reverse remodeling in selected patients.
- Diuretics reduce congestion, preload, and filling pressures; they are essential for symptom control but work through a different mechanism than reverse-remodeling therapies.
- CRT can reduce secondary MR in appropriately selected patients with LBBB, QRS prolongation, or significant dyssynchrony.
- The Secondary MR Intervention Navigator requires GDMT optimization before intervention evaluation by design — not as a barrier.
- Perioperatively, a patient who has never received optimized HF therapy is not the same as a patient who remains symptomatic despite maximum tolerated GDMT.
When to read this
You are evaluating a patient with secondary MR for elective noncardiac surgery and wondering why the recommendation begins with GDMT optimization rather than valve evaluation. Also read this if you want to understand why the Secondary MR Intervention Navigator includes a GDMT gate.
How GDMT can change secondary MR
In ventricular functional secondary MR, the underlying mechanism is LV dilation and papillary muscle displacement — which tethers the leaflets away from the coaptation point. The leaflets are not the primary problem; the ventricle has changed shape. Anything that reduces LV volume, lowers wall stress, and improves contractile function and synchrony reduces the geometric basis for regurgitation.
ACEi/ARB/ARNI, beta-blockers, MRA, and SGLT2 inhibitors can improve HF outcomes and may promote reverse remodeling through neurohormonal inhibition, afterload reduction, and favorable effects on LV volume and loading conditions. Diuretics reduce congestion and preload, improving symptoms and filling pressures — an essential part of HF management, though working by a different mechanism than the disease-modifying therapies above.
Studies and reviews report meaningful MR reduction in a substantial subset of patients after GDMT optimization, with estimates varying across populations and therapy intensity. Reports suggest that roughly a third to half of patients may experience significant MR reduction or stabilization — though the exact proportion depends on patient selection, baseline severity, and how thoroughly HF therapy is optimized. The practical point is not the precise number: secondary MR can change after HF therapy is improved, and proceeding to valve intervention before optimization exposes patients to procedural risk for a problem that may have improved with medical therapy.
The role of CRT
In patients with HFrEF and LBBB, QRS prolongation, or significant dyssynchrony, cardiac resynchronization therapy can reduce secondary MR by improving LV synchrony, reducing LV size, and improving papillary muscle coordination. In appropriately selected patients, MR may improve by one or more grades after CRT — though the effect depends on electrical substrate, QRS duration, LV dyssynchrony, and the degree of reverse remodeling achieved. Before TEER or surgical mitral intervention is considered in a patient with reduced EF and LBBB or QRS prolongation, CRT eligibility should be assessed.
When GDMT is not sufficient
GDMT does not eliminate secondary MR in every patient. Some patients remain symptomatic with confirmed severe secondary MR despite maximum tolerated HF therapy. In these patients, valve-directed therapy — TEER, or surgical mitral intervention when another cardiac surgery such as CABG is being performed — enters the discussion.
The COAPT trial showed that TEER reduced HF hospitalizations and mortality in carefully selected patients with HFrEF and severe secondary MR who remained symptomatic despite maximally tolerated GDMT. The key point: COAPT supports TEER on top of optimized GDMT — not instead of it. The efficacy of TEER in that trial was demonstrated in a population where maximum tolerated HF therapy was already in place.
GDMT optimization takes time — plan accordingly
Reverse remodeling and MR improvement after GDMT may take months. Reassessment after approximately 3–6 months of optimized therapy is often appropriate when the clinical situation allows. For elective noncardiac surgery, if GDMT has not been optimized, consider whether the operation can be staged or deferred — especially when symptoms, pulmonary pressure, LV function, or RV function are marginal. If surgery is urgent or time-sensitive, optimize what can be optimized, clarify residual risk, and coordinate planning among anesthesia, cardiology, surgery, and the HF team when needed.
Apply this in practice
Use the Secondary MR Intervention Navigator after severity and GDMT status are confirmed.
Secondary MR Intervention Navigator